2019
DOI: 10.2147/ott.s198946
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Ovarian cancer is the deadliest gynecologic malignancy, which poses a great threat to female health. Anti-angiogenic therapy could bring clinical benefit for patients with ovarian cancer. Apatinib, an oral small-molecule vascular endothelial growth factor receptor-2 inhibitor, has shown notable therapeutic effect in a wide variety of tumors. We report a woman with advanced ovarian cancer who received apatinib at 250 mg/day after failure of multiple-line treatment regimens, followed by discussion through review… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

1
5
0

Year Published

2019
2019
2023
2023

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 6 publications
(6 citation statements)
references
References 52 publications
1
5
0
Order By: Relevance
“…antiangiogenesis drug in China; it has been reported to be effective in various solid tumors. In line with previous case reports that apatinib has potential antitumor activity in patients with OC [25][26][27][28][29][30], we found it to be effective against OC cell proliferation in both a time-and concentrationdependent manner in vitro. Similarly, apatinib has been found to inhibit cell growth in breast cancer [8], NSCLC [9], colon cancer [10], hepatocellular carcinoma [11], pancreatic cancer [12], anaplastic thyroid cancer [13,14], osteosarcoma [15], and OC [31].…”
supporting
confidence: 92%
“…antiangiogenesis drug in China; it has been reported to be effective in various solid tumors. In line with previous case reports that apatinib has potential antitumor activity in patients with OC [25][26][27][28][29][30], we found it to be effective against OC cell proliferation in both a time-and concentrationdependent manner in vitro. Similarly, apatinib has been found to inhibit cell growth in breast cancer [8], NSCLC [9], colon cancer [10], hepatocellular carcinoma [11], pancreatic cancer [12], anaplastic thyroid cancer [13,14], osteosarcoma [15], and OC [31].…”
supporting
confidence: 92%
“…The China Food and Drug Administration recommended apatinib as a third-line treatment for advanced gastric and gastroesophageal junction adenocarcinoma in 2015. Besides, apatinib shows excellent potential in various solid tumors, such as non-small cell lung cancer ( 23 ), breast cancer ( 24 ), hepatocellular carcinoma ( 3 ), pancreatic cancer ( 25 ), and ovarian cancer ( 26 ). Adverse reactions to apatinib include hypertension, hand-foot syndrome, albuminuria, fatigue, anorexia, and elevated transaminase level; most of these adverse events are of grade1-2, which can be relieved by drug withdrawal or reduction ( 3 , 27 ).…”
Section: Discussionmentioning
confidence: 99%
“…However, the application of apatinib in ovarian cancer is still in the stage of the clinical study. There are several case reports and clinical studies (n=9~29) focused on apatinib therapy in patients with recurrent platinum-resistant ovarian cancer 8 - 10 , 21 . As reported in the above literature, the ORR and DCR of apatinib monotherapy could reach 18.2~41.4% and 47.1~81.8% respectively 8 - 10 .…”
Section: Discussionmentioning
confidence: 99%